Our Goals
Patients have always been the centre of physicians’ and researchers’ work, but at ILCA our goal is to make patients the heart of our decisions. The process to make this happen is articulated and made of different actions, in particular our aim is to:
- Partner with patients to provide them and specialised professionals education
- Raise awareness among the general population and those in the field who are not fully conscious of liver cancer problems
- Cooperate with patients’ associations to expose to politicians how to improve liver cancer prevention, diagnosis and treatment services
- Look for partners and funding to help supporting data to ensure liver cancer is high on the agenda for policy makers and healthcare authorities
ILCA Advocacy Leader
Manon Allaire
Dr. Manon Allaire is Doctor of Medecine in La Pitié Salpétrière Hospital in Paris, headed by Pr. Thabut. She focuses on teaching and research in hepatocellular carcinoma with focus in portal hypertension and systemic therapy. Dr Allaire obtained her medical degree in Hepatology and Gastroenterology in 2015 and her complementary medical degree in Medical Oncology in 2015.
She is responsible of the Department of primary liver tumor in La Pitié Salpétrière Hospital, and of clinical and translational trials focus on primary liver tumor. Dr Allaire is also member of the Proliferation, Stress and Liver Physiopathology unit in the group of Dr C. Desdouets in the Centre de Recherche des Cordeliers in Paris. Her team aim to study new immune biomarkers to predict response to immunotherapy and the impact of portal hypertension on the management of hepatocellular carcinoma.
ILCA Advocacy Patient Experts
- Jordi Bruix
- Bruno Sangro
- Shishir Shetty
- Ken Liu
ILCA Advocacy Paper
Disparities in access to systemic therapies for patients with
hepatocellular carcinoma: an analysis from the International
Liver Cancer Association
The ILCA advocacy has published a collaborative paper in The Lancet Regional Health – Europe. The paper examines global inequalities in access to systemic therapies for hepatocellular carcinoma, highlighting the need for coordinated international efforts to overcome regulatory, financial, and infrastructural barriers to treatment.
Round Table on Multidisciplinarity in treating liver cancer. A 360º perspective.
Presentation from the ILCA 2024 Annual Conference
As part of our ongoing commitment, at the ILCA Annual Conference 2024 in Toronto, we focused many of our discussions on the needs of our patients. Don’t miss the insightful Advocacy Session from #ILCA24!
Watch the full video from the ILCA 2023 Annual Conference.
Presentation from the ILCA 2023 Annual Conference
Patients have always been the centre of physicians’ and researchers’ work, but at ILCA our goal is to make patients the heart of our decisions.
Today’s world is one of rising healthcare costs and policy changes – and the need for advocacy by ILCA is greater than ever. There is simply no organisation better suited and more credible than ILCA to represent the liver cancer community and to lead the conversation around liver cancer prevention, diagnosis, and treatment. This role is ILCA’s, and we have taken the proper steps in this direction. Our goal is not just to bring awareness to liver cancer; we want to exceed that through developing a policy agenda that can be the model for nations to follow around the world.
Watch the full video from the ILCA 2023 Annual Conference.
ILCA Advocacy Paper
Paper Presentation at ILCA 2022 Annual Conference
As part of our Patient Advocacy strategy, ILCA is developing a series of ILCA Position Papers focused on access to treatment: 10 principles for improving access to treatment. This advocacy was launched at the ILCA Annual Conference with DiCE, ELPA and GLI and the first document has been presented at the ILCA AC 2022.
Watch the full video from ILCA 2022 Annual Conference to hear directly from our passionate experts the launch of ILCA Advocacy programme.
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association
The ILCA advocacy paper is now published in the Journal of Hepatology. It lays out the recommended approaches to the societal management of HCC based on the economic status of a given region and it is divided into the following sections:
- Causes of HCC
- Prevention
- Surveillance
- Diagnosis
- Staging
- Treatment
- Research
Summary:
Hepatocellular carcinoma (HCC) is a major public health problem worldwide for which the incidence and mortality are similar, pointing to the lack of effective treatment options. Knowing the different issues involved in the management of HCC, from risk factors to screening and management, is essential to improve the prognosis and quality of life of affected individuals. This document summarises the current state of knowledge and the unmet needs for all the different stakeholders in the care of liver cancer, meaning patients, relatives, physicians, regulatory agencies and health authorities so that optimal care can be delivered to patients. The document was commissioned by the International Liver Cancer Association and was reviewed by senior members, including two ex-presidents of the Association. This document lays out the recommended approaches to the societal management of HCC based on the economic status of a given region.
Other ILCA Advocacy Activities
25 October 2023 – “Together, Ensuring Deserved Care for Every Liver Cancer Patient”
Lorenza Rimassa and Manon Allaire – both part of the driving force behind ILCA – were involved in the online event, “Together, Ensuring Deserved Care for Every Liver Cancer Patient,” organised by Digestive Cancers Europe.
They joined leading experts, researchers, and patient advocates to discuss the latest advancements in liver cancer research, screening, early diagnosis, and innovative treatment approaches.
12 October 2022 – Liver Cancer: No Patient Left Behind, Optimising the European Response
ILCA has supported Digestive Cancers Europe (DiCE) and European Liver Patients’ Association (ELPA) in hosting a high-level European policy event – Liver Cancer: No Patient Left Behind, Optimising the European Response.
This event has been a high-valuable moment that reunited experts, policymakers, patients, and other stakeholders active in the field of liver cancer. On this occasion our continuous commitment was addressed to the exploration of solutions to ensure that no patient in Europe is left behind.
18th November 2022: ELPA Stakeholders Meeting with the presence of ILCA
ILCA has been invited to ELPA Stakeholders meeting to present its objectives and to share ILCA’s programme for 2023.